NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.17
  • Forecasted Upside: 102.93 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.01
▼ -0.05 (-0.99%)
1 month | 3 months | 12 months
Get New Adamas Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.17
▲ +102.93% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Adamas Pharmaceuticals in the last 3 months. The average price target is $10.17, with a high forecast of $12.50 and a low forecast of $6.00. The average price target represents a 102.93% upside from the last price of $5.01.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Adamas Pharmaceuticals. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/23/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
3/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/20/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightBoost Price TargetBuy$10.00 ➝ $12.00Medium
i
Rating by R. Selvaraju at HC Wainwright
5/13/2021SVB LeerinkReiterated RatingBuy$6.00High
i
2/2/2021HC WainwrightBoost Price TargetBuy$10.00 ➝ $12.00Low
i
1/28/2021Northland SecuritiesBoost Price Target$7.50 ➝ $12.50Medium
i
1/14/2021Needham & Company LLCReiterated RatingHoldLow
i
8/10/2020William BlairReiterated RatingBuyHigh
i
Rating by Tim Lugo at William Blair
8/7/2020Needham & Company LLCReiterated RatingNeutral ➝ HoldHigh
i
8/7/2020Northland SecuritiesReiterated RatingBuy$7.50High
i
6/5/2020HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/5/2020William BlairReiterated RatingBuyHigh
i
Rating by Tim Lugo at William Blair
5/8/2020Needham & Company LLCReiterated RatingHoldLow
i
5/8/2020HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/18/2019HC WainwrightReiterated RatingBuy$30.00 ➝ $10.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/17/2019Needham & Company LLCReiterated RatingHoldHigh
i
12/17/2019Cantor FitzgeraldReiterated RatingNeutral$8.00 ➝ $7.00High
i
Rating by C. Duncan at Cantor Fitzgerald
12/9/2019Evercore ISIReiterated RatingBuyMedium
i
12/2/2019HC WainwrightReiterated RatingBuy$30.00High
i
11/8/2019JMP SecuritiesLower Price TargetOutperform$16.00High
i
11/8/2019Needham & Company LLCReiterated RatingHoldHigh
i
11/8/2019Northland SecuritiesReiterated RatingBuy$15.00High
i
Rating by Carl Byrnes at Northland Securities
9/30/2019Bank of AmericaDowngradeNeutral ➝ Underperform$9.00 ➝ $5.00High
i
9/13/2019Northland SecuritiesSet Price TargetBuy$15.00Medium
i
Rating by Carl Byrnes at Northland Securities
9/9/2019Cantor FitzgeraldInitiated CoverageNeutral$8.00 ➝ $8.00Medium
i
Rating by C. Duncan at Cantor Fitzgerald
8/12/2019Evercore ISIReiterated RatingBuy$55.00Medium
i
8/9/2019CowenSet Price TargetHold$5.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
5/28/2019HC WainwrightLower Price TargetBuy$40.00 ➝ $30.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/24/2019MizuhoReiterated RatingSell$5.00Low
i
3/5/2019Piper Jaffray CompaniesSet Price TargetBuy$23.00High
i
Rating by David Amsellem at Piper Jaffray Companies
3/5/2019HC WainwrightSet Price TargetBuy$40.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/5/2019Northland SecuritiesReiterated RatingBuy$28.00Low
i
3/5/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
3/5/2019CowenDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00High
i
Rating by Ken Cacciatore at Cowen Inc
3/5/2019MizuhoDowngradeNeutral ➝ Underperform$11.00 ➝ $5.00High
i
1/14/2019HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/11/2019MizuhoReiterated RatingHold$11.00Medium
i
11/12/2018SVB LeerinkInitiated CoverageOutperform$20.00Low
i
Rating by J. Sullivan at SVB Leerink LLC
11/5/2018HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/5/2018MizuhoDowngradeBuy ➝ Neutral$75.00 ➝ $18.00High
i
11/1/2018CowenSet Price TargetBuy$30.00High
i
Rating by Ken Cacciatore at Cowen Inc
10/19/2018SVB LeerinkReiterated RatingOutperformHigh
i
Rating by J. Sullivan at SVB Leerink LLC
10/5/2018Bank of AmericaDowngradeBuy ➝ Neutral$36.00 ➝ $25.00High
i
9/17/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/17/2018MizuhoReiterated RatingBuy$75.00Low
i
8/6/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by R. Selvaraju at HC Wainwright
7/16/2018HC WainwrightInitiated CoverageBuy$45.00Medium
i
Rating by R. Selvaraju at HC Wainwright
4/22/2018Piper Jaffray CompaniesSet Price TargetBuy$49.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
4/20/2018MizuhoReiterated RatingBuy$49.00Medium
i
4/4/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$31.00High
i
Rating by G. Porges at SVB Leerink LLC
3/27/2018Bank of AmericaInitiated CoverageBuy$39.00High
i
2/25/2018Needham & Company LLCSet Price TargetBuy$40.00Low
i
Rating by Serge Belanger at Needham & Company LLC
2/23/2018Noble FinancialReiterated RatingBuyLow
i
2/21/2018William BlairReiterated RatingOutperformLow
i
Rating by T. Lugo at William Blair
1/23/2018MizuhoReiterated RatingBuy$48.00High
i
12/19/2017Piper Jaffray CompaniesSet Price TargetBuy$52.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
12/13/2017CowenSet Price TargetBuy$55.00High
i
Rating by Ken Cacciatore at Cowen Inc
11/29/2017Northland SecuritiesInitiated CoverageOutperform ➝ OutperformLow
i
11/8/2017Noble FinancialBoost Price TargetBuy$33.00 ➝ $48.00N/A
i
Rating by Kumaraguru Raja at Noble Financial
10/30/2017Evercore ISIInitiated CoverageOutperformN/A
i
10/4/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00N/A
i
9/29/2017Noble FinancialReiterated RatingBuy ➝ Buy$33.00Low
i
Rating by Kumaraguru Raja at Noble Financial
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00Low
i
9/19/2017MizuhoReiterated RatingBuy ➝ Buy$26.00 ➝ $48.00High
i
9/17/2017Needham & Company LLCReiterated RatingBuy$38.00Medium
i
9/13/2017MizuhoReiterated RatingBuy$26.00 ➝ $48.00Low
i
9/5/2017MizuhoReiterated RatingBuy$26.00Low
i
9/1/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00Low
i
8/25/2017William BlairReiterated RatingOurperformHigh
i
8/25/2017JMP SecuritiesReiterated RatingMkt Outperform ➝ Outperform$29.00 ➝ $33.00High
i
8/25/2017CowenReiterated RatingOutperform$45.00 ➝ $55.00High
i
Rating by Ken Cacciatore at Cowen Inc
8/9/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Kumaraguru Raja at Noble Financial
8/9/2017CowenSet Price TargetBuy$45.00High
i
Rating by Ken Cacciatore at Cowen Inc
6/6/2017MizuhoReiterated RatingBuy$26.00Low
i
5/28/2017CowenReiterated RatingOutperform$45.00Low
i
5/12/2017Noble FinancialReiterated RatingBuyLow
i
3/15/2017MizuhoReiterated RatingTop Pick$26.00Low
i
2/21/2017MizuhoReiterated RatingBuy$26.00N/A
i
1/5/2017MizuhoReiterated RatingBuy$26.00N/A
i
11/7/2016MizuhoReiterated RatingBuy$26.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Jason Butler at JMP Securities
9/23/2016MizuhoReiterated RatingBuy$26.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/8/2016MizuhoBoost Price TargetBuy$22.00 ➝ $26.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
7/22/2016Noble FinancialReiterated RatingBuy$25.00N/A
i
Rating by Nathan Cali at Noble Financial
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00N/A
i
6/28/2016Noble FinancialReiterated RatingBuy$25.00N/A
i
Rating by Nathan Cali at Noble Financial
6/23/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/22/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Vamil Divan at Credit Suisse Group AG
6/17/2016Noble FinancialInitiated CoverageBuy$25.00N/A
i
6/16/2016MizuhoUpgradeNeutral ➝ Buy$22.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
(Data available from 6/16/2016 forward)
Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $5.01
$4.86
$5.09

50 Day Range

MA: $5.18
$4.52
$5.96

52 Week Range

Now: $5.01
$2.43
$9.15

Volume

320,176 shs

Average Volume

570,143 shs

Market Capitalization

$207.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Adamas Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Adamas Pharmaceuticals in the last twelve months: HC Wainwright, Needham & Company LLC, Northland Securities, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ADMS.

What is the current price target for Adamas Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Adamas Pharmaceuticals in the last year. Their average twelve-month price target is $10.17, suggesting a possible upside of 102.9%. Northland Securities has the highest price target set, predicting ADMS will reach $12.50 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $6.00 for Adamas Pharmaceuticals in the next year.
View the latest price targets for ADMS.

What is the current consensus analyst rating for Adamas Pharmaceuticals?

Adamas Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADMS will outperform the market and that investors should add to their positions of Adamas Pharmaceuticals.
View the latest ratings for ADMS.

What other companies compete with Adamas Pharmaceuticals?

How do I contact Adamas Pharmaceuticals' investor relations team?

Adamas Pharmaceuticals' physical mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company's listed phone number is 510-450-3500 and its investor relations email address is [email protected] The official website for Adamas Pharmaceuticals is www.adamaspharma.com.